{"id":84255,"date":"2026-01-13T19:04:12","date_gmt":"2026-01-13T17:04:12","guid":{"rendered":"https:\/\/gulftech-news.com\/en\/?p=84255"},"modified":"2026-01-14T13:42:03","modified_gmt":"2026-01-14T11:42:03","slug":"wegovy-obesity-treatment-oman","status":"publish","type":"post","link":"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/","title":{"rendered":"Wegovy\u00ae (Semaglutide 2.4mg) an Obesity Treatment for People Living with Obesity in Oman"},"content":{"rendered":"\n

Muscat, Gulf Tech News :<\/strong><\/p>\n\n\n\n

Novo Nordisk,<\/a> the Danish leading global healthcare company renowned for its expertise in treating chronic diseases such as diabetes and obesity, announced the availability of Wegovy\u00ae in Oman, at a press conference held on Jan 13, 2026.
\u00a0
The event was attended by Novo Nordisk\u2019s General Manager for Gulf Emerging Markets Mr. Venkat Kalyan, The Chief Executive Officer of Muscat Pharmacy & Stores LLC Mr. Jose Sreedharan in the presence of Dr. Noor al Busaidi, President of Oman Diabetes Association & Director of National Diabetes & Endocrine Centre, Dr. Amira Al Kharousiyya Consultant Bariatric medicine at National Diabetes & Endocrine Centre, as well as Dr. Badr Al Hadrami, President of the Bariatric and Metabolic Surgery Society in Oman, along with distinguished guests and media representatives.
\u00a0
Obesity has emerged as a significant global epidemic, affecting approximately 1 billion individuals worldwide\u00b9. Obesity in the Gulf is rapidly unfolding with the highest rates globally\u00b2.
Adults in Oman living with obesity represent 36% of the population, and 71% of the population are overweight\u00b2. With seven out of ten adults in the country affected by weight-related conditions, clinically proven treatment options are expected to play a significant role in easing the burden on healthcare systems and enhancing the quality of life for Omani people.
\u00a0
Statements:
\u00a0
President of Oman Diabetes Association Sayyida Dr Noor Al Busaidi stated:
\u201cIn Oman, around 35% of the adult population are affected by obesity and another 66% of the population are either overweight or obese according to the National Health survey in 2017 and we are awaiting updates from the latest survey due to be published soon. We value the work with other stakeholders and partners including pharmaceutical partners in addressing this epidemic through enhancing multidisciplinary approach to care and building the health care professionals\u2019 knowledge and skill capacities, and with the introduction of advanced and proven treatments, We are optimistic that the launch of Wegovy\u00ae in Sultanate of Oman is an important step with great clinical management potentials. We will continue to work together to achieve our common goal and that is to limit the burden of obesity while working also on the prevention side, educating people and raising awareness and participating in obesity intervention programs.\u201d
\u00a0
<\/p>\n\n\n\n

Dr. Amira Al Kharousiyya Consultant Bariatric medicine at National Diabetes & Endocrine Centre shared that:\u201cObesity represents one of the most significant threats to population health and healthcare sustainability in Oman. Addressing it requires leadership, long\u2011term vision, and coordinated policy action across sectors. By prioritizing prevention, strengthening clinical care, and investing in evidence\u2011based strategies, the Ministry of Health can lead a transformative response-one that protects the health of current and future generations.
In this context, the introduction of modern anti\u2011obesity medications such as Wegovy\u00ae\ufe0f (semaglutide 2.4 mg) adds an important dimension to the national treatment pathway. When used appropriately and under medical supervision, Wegovy\u00ae\ufe0f can support patients who need clinically proven options beyond lifestyle modification alone. Integrating such therapies into Oman\u2019s broader obesity\u2011management framework enhances treatment effectiveness, supports earlier intervention, and helps reduce long\u2011term complications.\u201d
\u00a0
President of the Oman Bariatric and Metabolic Surgery Society Dr. Badr Al Hadrami emphasized:
\u201cObesity is a serious and chronic disease, and a leading contributor to multiple comorbidities such as type 2 diabetes and cardiovascular conditions. He noted that \u201cOman ranks among the highest globally in obesity prevalence, which underscores the urgent need for collaborative efforts across all sectors to address this growing public health challenge\u201d. Also highlighted the importance of GLP-1 therapies like Wegovy\u00ae\ufe0f, which play a vital role in improving health outcomes and saving lives by offering patients an effective tool to manage obesity<\/p>\n","protected":false},"excerpt":{"rendered":"

Muscat, Gulf Tech News : Novo Nordisk, the Danish leading global healthcare company renowned for its expertise in treating chronic diseases such as diabetes and obesity, announced the availability of Wegovy\u00ae in Oman, at a press conference held on Jan 13, 2026.\u00a0The event was attended by Novo Nordisk\u2019s General Manager for Gulf Emerging Markets Mr. …<\/p>\n","protected":false},"author":2,"featured_media":84256,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[640,1],"tags":[3142,4849,4850,4848],"class_list":["post-84255","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tie-foods","category-uncategorized","tag-novo-nordisk","tag-obesity-treatment","tag-oman","tag-wegovy"],"yoast_head":"\nNovo Nordisk Launches Wegovy\u00ae Obesity Treatment in Oman<\/title>\n<meta name=\"description\" content=\"Novo Nordisk announces the availability of Wegovy\u00ae (semaglutide 2.4 mg) in Oman, offering a clinically proven treatment option to support obesity management and public health.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Launches Wegovy\u00ae Obesity Treatment in Oman\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk announces the availability of Wegovy\u00ae (semaglutide 2.4 mg) in Oman, offering a clinically proven treatment option to support obesity management and public health.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/\" \/>\n<meta property=\"og:site_name\" content=\"Gulf Tech News\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-13T17:04:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-14T11:42:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/01\/WhatsApp-Image-2026-01-13-at-18.31.58.jpeg?v=1768323598\" \/>\n\t<meta property=\"og:image:width\" content=\"1077\" \/>\n\t<meta property=\"og:image:height\" content=\"718\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"bessan helmi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"bessan helmi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/\",\"url\":\"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/\",\"name\":\"Novo Nordisk Launches Wegovy\u00ae Obesity Treatment in Oman\",\"isPartOf\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/01\/WhatsApp-Image-2026-01-13-at-18.31.58.jpeg?v=1768323598\",\"datePublished\":\"2026-01-13T17:04:12+00:00\",\"dateModified\":\"2026-01-14T11:42:03+00:00\",\"author\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/c033626e357b2f7e127eac0570ddc05c\"},\"description\":\"Novo Nordisk announces the availability of Wegovy\u00ae (semaglutide 2.4 mg) in Oman, offering a clinically proven treatment option to support obesity management and public health.\",\"breadcrumb\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/#primaryimage\",\"url\":\"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/01\/WhatsApp-Image-2026-01-13-at-18.31.58.jpeg?v=1768323598\",\"contentUrl\":\"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/01\/WhatsApp-Image-2026-01-13-at-18.31.58.jpeg?v=1768323598\",\"width\":1077,\"height\":718},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/gulftech-news.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wegovy\u00ae (Semaglutide 2.4mg) an Obesity Treatment for People Living with Obesity in Oman\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/gulftech-news.com\/en\/#website\",\"url\":\"https:\/\/gulftech-news.com\/en\/\",\"name\":\"Gulf Tech News\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/gulftech-news.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/c033626e357b2f7e127eac0570ddc05c\",\"name\":\"bessan helmi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bb1e09a6f094e0fa605073926f8ad9eb228a8b0aacd381fda782c562612428cf?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bb1e09a6f094e0fa605073926f8ad9eb228a8b0aacd381fda782c562612428cf?s=96&d=mm&r=g\",\"caption\":\"bessan helmi\"},\"url\":\"https:\/\/gulftech-news.com\/en\/author\/bessan-helmi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novo Nordisk Launches Wegovy\u00ae Obesity Treatment in Oman","description":"Novo Nordisk announces the availability of Wegovy\u00ae (semaglutide 2.4 mg) in Oman, offering a clinically proven treatment option to support obesity management and public health.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk Launches Wegovy\u00ae Obesity Treatment in Oman","og_description":"Novo Nordisk announces the availability of Wegovy\u00ae (semaglutide 2.4 mg) in Oman, offering a clinically proven treatment option to support obesity management and public health.","og_url":"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/","og_site_name":"Gulf Tech News","article_published_time":"2026-01-13T17:04:12+00:00","article_modified_time":"2026-01-14T11:42:03+00:00","og_image":[{"width":1077,"height":718,"url":"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/01\/WhatsApp-Image-2026-01-13-at-18.31.58.jpeg?v=1768323598","type":"image\/jpeg"}],"author":"bessan helmi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"bessan helmi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/","url":"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/","name":"Novo Nordisk Launches Wegovy\u00ae Obesity Treatment in Oman","isPartOf":{"@id":"https:\/\/gulftech-news.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/#primaryimage"},"image":{"@id":"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/#primaryimage"},"thumbnailUrl":"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/01\/WhatsApp-Image-2026-01-13-at-18.31.58.jpeg?v=1768323598","datePublished":"2026-01-13T17:04:12+00:00","dateModified":"2026-01-14T11:42:03+00:00","author":{"@id":"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/c033626e357b2f7e127eac0570ddc05c"},"description":"Novo Nordisk announces the availability of Wegovy\u00ae (semaglutide 2.4 mg) in Oman, offering a clinically proven treatment option to support obesity management and public health.","breadcrumb":{"@id":"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/#primaryimage","url":"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/01\/WhatsApp-Image-2026-01-13-at-18.31.58.jpeg?v=1768323598","contentUrl":"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/01\/WhatsApp-Image-2026-01-13-at-18.31.58.jpeg?v=1768323598","width":1077,"height":718},{"@type":"BreadcrumbList","@id":"https:\/\/gulftech-news.com\/en\/2026\/01\/13\/wegovy-obesity-treatment-oman\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/gulftech-news.com\/en\/"},{"@type":"ListItem","position":2,"name":"Wegovy\u00ae (Semaglutide 2.4mg) an Obesity Treatment for People Living with Obesity in Oman"}]},{"@type":"WebSite","@id":"https:\/\/gulftech-news.com\/en\/#website","url":"https:\/\/gulftech-news.com\/en\/","name":"Gulf Tech News","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/gulftech-news.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/c033626e357b2f7e127eac0570ddc05c","name":"bessan helmi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bb1e09a6f094e0fa605073926f8ad9eb228a8b0aacd381fda782c562612428cf?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bb1e09a6f094e0fa605073926f8ad9eb228a8b0aacd381fda782c562612428cf?s=96&d=mm&r=g","caption":"bessan helmi"},"url":"https:\/\/gulftech-news.com\/en\/author\/bessan-helmi\/"}]}},"_links":{"self":[{"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/posts\/84255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/comments?post=84255"}],"version-history":[{"count":3,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/posts\/84255\/revisions"}],"predecessor-version":[{"id":84317,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/posts\/84255\/revisions\/84317"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/media\/84256"}],"wp:attachment":[{"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/media?parent=84255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/categories?post=84255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/tags?post=84255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}